Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia - PubMed
5 hours ago
- #CAR-T therapy
- #leukemia
- #relapse
- Tisagenlecleucel (tisa-cel) improves outcomes in pediatric, adolescent, and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL).
- 30-50% of patients experience early failure or relapse post-tisa-cel therapy.
- CD19 antigen loss is associated with lower complete remission rates after salvage therapy.
- Median overall survival (OS) post-failure is 14.5 months, with a 2-year OS of 37.4%.
- Patients with measurable residual disease at salvage initiation have better 2-year OS (61.9%) compared to those with overt disease (20.7%).
- High pre-infusion tumor burden and prior inotuzumab ozogamicin exposure are linked to inferior OS.
- Hematopoietic stem cell transplantation carries significant risks, with treatment-related toxicity deaths reported.
- The study underscores the poor prognosis of tisa-cel failures and the need for novel treatment strategies.